First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy.

VandenDriessche, Thierry; Pipe, Steven W; Pierce, Glenn F; Kaczmarek, Radoslaw

VandenDriessche, Thierry; Pipe, Steven W; Pierce, Glenn F; Kaczmarek, Radoslaw.

Afiliação

VandenDriessche T; Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium; Center for Molecular & Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium. Electronic address: thierry.vandendriessche@vub.be.
Pipe SW; Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA.
Pierce GF; World Federation of Hemophilia, Montreal, QC, Canada.
Kaczmarek R; Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA. Electronic address: rkaczmar@iu.edu.

Mol Ther ; 30(11): 3335-3336, 2022 11 02.

Article em En | MEDLINE | ID: mdl-36261044

Assuntos

Hemofilia A; Humanos; União Europeia; Hemofilia A/genética; Hemofilia A/terapia; Aprovação de Drogas; Terapia Genética; Marketing

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hemofilia A Limite: Humans Idioma: En Revista: Mol Ther Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google